Case ReportsAripiprazole in a Patient of PLA2G6-Associated Neurodegeneration With PsychosisHuang, Mao-Hsuan MD*; Chiu, Yu-Chuan MD†; Tsai, Chia-Fen MD, PhD*‡Author Information *Department of Psychiatry, Taipei Veterans General Hospital; †Department of Psychiatry, MacKay Memorial Hospital; and ‡Faculty of Medicine, National Yang-Ming University Schools of Medicine, Taipei, Taiwan. Address correspondence and reprint requests to Chia-Fen Tsai, MD, PhD, Department of Psychiatry, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Beitou District, Taipei 112, Taiwan; E-mail: email@example.com Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare. Consent of the individual described in our case report had been obtained. Clinical Neuropharmacology: 7/8 2018 - Volume 41 - Issue 4 - p 136-137 doi: 10.1097/WNF.0000000000000284 Buy Metrics Abstract PLA2G6-associated neurodegeneration is a major subtype of neurodegeneration with brain iron accumulation. Patients with PLA2G6-associated neurodegeneration usually present degenerative motor symptoms with neuropsychiatric disturbance. This report presents a patient with PLA2G6-related dystonia-parkinsonism, who had neuropsychiatric symptoms preceding movement symptoms. Antipsychotic drug was prescribed, and he developed parkinsonism years later. Differential diagnosis between drug-induced parkinsonism and PLA2G6-related dystonia-parkinsonism could be challenging. PLA2G6 sequencing has to be considered facing a patient with adulthood parkinsonism, especially when it is associated with initial psychiatric symptoms. Our case highlights a common problem treating psychiatric symptoms in neurodegenerative diseases that lead to parkinsonism. The use of antipsychotics requires a special caution in these patients because it may cause extrapyramidal symptoms. Aripiprazole had therapeutic effect on both mood and psychotic symptoms and less impact on motor features, which may be considered an ideal pharmacological approach in treating these patients. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.